• Publications
  • Influence
New horizons in adjuvants for vaccine development.
Over the last decade, there has been a flurry of research on adjuvants for vaccines, and several novel adjuvants are now in licensed products or in late stage clinical development. The success ofExpand
  • 576
  • 31
  • PDF
Second-generation vaccines against leishmaniasis.
Several species of Leishmania cause human diseases that range from self-healing cutaneous lesions to fatal visceral leishmaniasis, mucosal leishmaniasis and diffuse cutaneous leishmaniasis. DrugExpand
  • 245
  • 17
Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant
Innate immune responses to vaccine adjuvants based on lipopolysaccharide (LPS), a component of Gram-negative bacterial cell walls, are driven by Toll-like receptor (TLR) 4 and adaptor proteinsExpand
  • 235
  • 12
  • PDF
A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant Mycobacterium tuberculosis
A vaccine with a four-protein fusion peptide from Mycobacterium tuberculosis effectively boosts the current childhood TB vaccine and protects against drug-resistant TB. A Superior Shot forExpand
  • 233
  • 12
Leish-111f, a Recombinant Polyprotein Vaccine That Protects against Visceral Leishmaniasis by Elicitation of CD4+ T Cells
ABSTRACT The Leishmania-derived recombinant polyprotein Leish-111f or its three component proteins, thiol-specific antioxidant (TSA), Leishmania major stress-inducible protein 1 (LmSTI1), andExpand
  • 181
  • 11
Expression Cloning of an Immunodominant Family of Mycobacterium tuberculosis Antigens Using Human Cd4+ T Cells
Development of a subunit vaccine for Mycobacterium tuberculosis (Mtb) is likely to be dependent on the identification of T cell antigens that induce strong proliferation and interferon γ productionExpand
  • 127
  • 10
  • PDF
Taking toll: lipid A mimetics as adjuvants and immunomodulators.
Vaccine adjuvants based on the structure of lipid A, such as monophosphoryl lipid A (MLA), have proven to be safe and effective in inducing immune responses to heterologous proteins in animal andExpand
  • 231
  • 9
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Abstract Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of aExpand
  • 228
  • 9
  • PDF
Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys
  • S. Reed, R. Coler, +13 authors Y. Lobet
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences
  • 17 February 2009
The development of a vaccine for tuberculosis requires a combination of antigens and adjuvants capable of inducing appropriate and long-lasting T cell immunity. We evaluated Mtb72F formulated inExpand
  • 144
  • 7
  • PDF
Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens
The majority of vaccine candidates in clinical development are highly purified proteins and peptides relying on adjuvants to enhance and/or direct immune responses. Despite the acknowledged need forExpand
  • 124
  • 7